Patents by Inventor Markus Hanner

Markus Hanner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130280288
    Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.
    Type: Application
    Filed: April 17, 2013
    Publication date: October 24, 2013
    Inventors: ANDREAS MEINKE, ASTRID TEUBENBACHER, BEATRICE TSCHANUN, MANUEL ZERBS, MARKUS HANNER, JUTTA PIKALO, ESZTER NAGY, CARMEN GIEFING-KRELL, ALEXANDER VON GABAIN
  • Publication number: 20130243779
    Abstract: The present invention relates to a protective peptide of Enterococcus faecalis (E. faecalis) or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing an E. faecalis infection; and the use of said peptide for the isolation and/or purification and/or identification of an interaction partner of the peptide.
    Type: Application
    Filed: February 4, 2010
    Publication date: September 19, 2013
    Applicant: Intercell AG
    Inventors: Eszter Nagy, Beatrice Tschanun, Markus Hanner, Manfred Berger, Andreas Meinke, Alexander Von Gabain, Barbara Murray, Kavindra Singh
  • Patent number: 8529910
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: September 10, 2013
    Assignee: Intercell Austria AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Dieter Gelbmann
  • Publication number: 20130230526
    Abstract: The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from Klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection.
    Type: Application
    Filed: July 6, 2012
    Publication date: September 5, 2013
    Applicant: Intercell AG
    Inventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander von Gabain
  • Patent number: 8449892
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, and methods for isolating such antigens and specific uses thereof.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: May 28, 2013
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Markus Horky, Sabine Kallenda, Sonja Prustomersky
  • Patent number: 8445001
    Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: May 21, 2013
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Astrid Teubenbacher, Beatrice Tschanun, Manuel Zerbs, Markus Hanner, Jutta Pikalo, Eszter Nagy, Carmen Giefing, Alexander Von Gabain
  • Patent number: 8431128
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: April 30, 2013
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Dieter Gelbmann
  • Patent number: 8372411
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pneumoniae, methods for isolating such antigens and specific uses thereof.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: February 12, 2013
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Shailesh Dewasthaly, Ulrike Stierschneider
  • Publication number: 20130011403
    Abstract: The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from Klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection.
    Type: Application
    Filed: July 6, 2012
    Publication date: January 10, 2013
    Applicant: Intercell AG
    Inventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander von Gabain
  • Publication number: 20120294881
    Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.
    Type: Application
    Filed: August 3, 2012
    Publication date: November 22, 2012
    Applicant: Intercell AG
    Inventors: Andreas Meinke, Astrid Teubenbacher, Beatrice Tschanun, Manuel Zerbs, Markus Hanner, Jutta Pikalo, Eszter Nagy, Carmen Giefing-Kröll, Alexander Von Gabain
  • Patent number: 8241643
    Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: August 14, 2012
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Astrid Teubenbacher, Beatrice Senn, Manuel Zerbs, Markus Hanner, Jutta Pikalo, Eszter Nagy, Carmen Giefing-Krōll, Alexander Von Gabain
  • Patent number: 8236326
    Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Klebsiella species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. Moreover, the present invention provides antibodies binding to such antigen, a hybridoma cell producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of reducing or inhibiting the interaction activity of such antigen, methods for diagnosing an infection and methods for the treatment or prevention of an infection.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: August 7, 2012
    Assignee: Intercell AG
    Inventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander von Gabain
  • Publication number: 20120141487
    Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a Moraxella catarrhalis (Meat) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Moraxella catarrhalis species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell which expresses such antigen. More specifically, such antigens are produced by or associated with bacterial infections caused by Moraxella catarrhalis.
    Type: Application
    Filed: May 28, 2010
    Publication date: June 7, 2012
    Applicant: Intercell AG
    Inventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Julia Flor, Birgit Noiges, Wolfgang Schueler, Ulrike Schirmer, Verena Salletmayer, Mario Aistleithner, Stefan Seidel, Martin Oleksiewicz
  • Publication number: 20120082674
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.
    Type: Application
    Filed: December 12, 2011
    Publication date: April 5, 2012
    Applicant: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Dieter Gelbmann
  • Publication number: 20120045457
    Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable Haemophilus influenzae (H. influenzae) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a nontypable Haemophilus influenzae species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. More specifically such antigens are produced by or associated with bacterial infections caused by nontypable Haemophilus influenzae.
    Type: Application
    Filed: February 15, 2010
    Publication date: February 23, 2012
    Applicant: INTERCELL AG
    Inventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Michaela Weissgram, Birgit Noiges, Stefan Seidel, Julia Bacher, Christina Satke, Wolfgang Schueler, Martin Oleksiewicz
  • Publication number: 20110243978
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.
    Type: Application
    Filed: March 28, 2011
    Publication date: October 6, 2011
    Applicant: INTERCELL AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Dieter Gelbmann
  • Publication number: 20110236410
    Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Klebsiella species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. Moreover, the present invention provides antibodies binding to such antigen, a hybridoma cell producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of reducing or inhibiting the interaction activity of such antigen, methods for diagnosing an infection and methods for the treatment or prevention of an infection.
    Type: Application
    Filed: April 29, 2008
    Publication date: September 29, 2011
    Applicant: Intercell AG
    Inventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander von Gabain
  • Publication number: 20110159027
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, and methods for isolating such antigens and specific uses thereof.
    Type: Application
    Filed: March 7, 2011
    Publication date: June 30, 2011
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Markus Horky, Sabine Kallenda, Sonja Prustomersky
  • Publication number: 20110091494
    Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S.
    Type: Application
    Filed: March 17, 2009
    Publication date: April 21, 2011
    Applicant: Intercell AG
    Inventors: Andreas Meinke, Astrid Teubenbacher, Beatrice Senn, Manuel Zerbs, Markus Hanner, Jutta Pikalo, Eszter Nagy, Carmen Giefing, Alexander Von Gabain
  • Patent number: 7927607
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, and methods for isolating such antigens and specific uses thereof.
    Type: Grant
    Filed: September 3, 2008
    Date of Patent: April 19, 2011
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Markus Horky, Sabine Kallenda, Sonja Prustomersky